Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-01-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12931-018-0724-0 |
| _version_ | 1818943559562166272 |
|---|---|
| author | Peter R. Bremner Ruby Birk Noushin Brealey Afisi S. Ismaila Chang-Qing Zhu David A. Lipson |
| author_facet | Peter R. Bremner Ruby Birk Noushin Brealey Afisi S. Ismaila Chang-Qing Zhu David A. Lipson |
| author_sort | Peter R. Bremner |
| collection | DOAJ |
| description | Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the non-inferiority of single-inhaler FF/UMEC/VI versus FF/VI + UMEC using two inhalers. Methods Eligible patients with COPD (aged ≥40 years; ≥1 moderate/severe exacerbation in the 12 months before screening) were randomized (1:1; stratified by the number of long-acting bronchodilators [0, 1 or 2] per day during run-in) to receive 24-week FF/UMEC/VI 100/62.5/25 μg and placebo or FF/VI 100/25 μg + UMEC 62.5 μg; all treatments/placebo were delivered using the ELLIPTA inhaler once-daily in the morning. Primary endpoint: change from baseline in trough forced expiratory volume in 1 s (FEV1) at Week 24. The non-inferiority margin for the lower 95% confidence limit was set at − 50 mL. Results A total of 1055 patients (844 [80%] of whom were enrolled on combination maintenance therapy) were randomized to receive FF/UMEC/VI (n = 527) or FF/VI + UMEC (n = 528). Mean change from baseline in trough FEV1 at Week 24 was 113 mL (95% CI 91, 135) for FF/UMEC/VI and 95 mL (95% CI 72, 117) for FF/VI + UMEC; the between-treatment difference of 18 mL (95% CI -13, 50) confirmed FF/UMEC/VI’s was considered non-inferior to FF/VI + UMEC. At Week 24, the proportion of responders based on St George’s Respiratory Questionnaire Total score was 50% (FF/UMEC/VI) and 51% (FF/VI + UMEC); the proportion of responders based on the Transitional Dyspnea Index focal score was similar (56% both groups). A similar proportion of patients experienced a moderate/severe exacerbation in the FF/UMEC/VI (24%) and FF/VI + UMEC (27%) groups; the hazard ratio for time to first moderate/severe exacerbation with FF/UMEC/VI versus FF/VI + UMEC was 0.87 (95% CI 0.68, 1.12). The incidence of adverse events was comparable in both groups (48%); the incidence of serious adverse events was 10% (FF/UMEC/VI) and 11% (FF/VI + UMEC). Conclusions Single-inhaler triple therapy (FF/UMEC/VI) is non-inferior to two inhalers (FF/VI + UMEC) on trough FEV1 change from baseline at 24 weeks. Results were similar on all other measures of efficacy, health-related quality of life, and safety. Trial registration GSK study CTT200812; ClinicalTrials.gov NCT02729051 (submitted 31 March 2016). |
| first_indexed | 2024-12-20T07:29:15Z |
| format | Article |
| id | doaj.art-ccd29838d82b4091a09d185b46fc79d5 |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-12-20T07:29:15Z |
| publishDate | 2018-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-ccd29838d82b4091a09d185b46fc79d52022-12-21T19:48:27ZengBMCRespiratory Research1465-993X2018-01-0119111010.1186/s12931-018-0724-0Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority studyPeter R. Bremner0Ruby Birk1Noushin Brealey2Afisi S. Ismaila3Chang-Qing Zhu4David A. Lipson5University of Notre DameGSK, Stockley Park West, UxbridgeGSK, Stockley Park West, UxbridgeGSKGSK, Stockley Park West, UxbridgeGSKAbstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the non-inferiority of single-inhaler FF/UMEC/VI versus FF/VI + UMEC using two inhalers. Methods Eligible patients with COPD (aged ≥40 years; ≥1 moderate/severe exacerbation in the 12 months before screening) were randomized (1:1; stratified by the number of long-acting bronchodilators [0, 1 or 2] per day during run-in) to receive 24-week FF/UMEC/VI 100/62.5/25 μg and placebo or FF/VI 100/25 μg + UMEC 62.5 μg; all treatments/placebo were delivered using the ELLIPTA inhaler once-daily in the morning. Primary endpoint: change from baseline in trough forced expiratory volume in 1 s (FEV1) at Week 24. The non-inferiority margin for the lower 95% confidence limit was set at − 50 mL. Results A total of 1055 patients (844 [80%] of whom were enrolled on combination maintenance therapy) were randomized to receive FF/UMEC/VI (n = 527) or FF/VI + UMEC (n = 528). Mean change from baseline in trough FEV1 at Week 24 was 113 mL (95% CI 91, 135) for FF/UMEC/VI and 95 mL (95% CI 72, 117) for FF/VI + UMEC; the between-treatment difference of 18 mL (95% CI -13, 50) confirmed FF/UMEC/VI’s was considered non-inferior to FF/VI + UMEC. At Week 24, the proportion of responders based on St George’s Respiratory Questionnaire Total score was 50% (FF/UMEC/VI) and 51% (FF/VI + UMEC); the proportion of responders based on the Transitional Dyspnea Index focal score was similar (56% both groups). A similar proportion of patients experienced a moderate/severe exacerbation in the FF/UMEC/VI (24%) and FF/VI + UMEC (27%) groups; the hazard ratio for time to first moderate/severe exacerbation with FF/UMEC/VI versus FF/VI + UMEC was 0.87 (95% CI 0.68, 1.12). The incidence of adverse events was comparable in both groups (48%); the incidence of serious adverse events was 10% (FF/UMEC/VI) and 11% (FF/VI + UMEC). Conclusions Single-inhaler triple therapy (FF/UMEC/VI) is non-inferior to two inhalers (FF/VI + UMEC) on trough FEV1 change from baseline at 24 weeks. Results were similar on all other measures of efficacy, health-related quality of life, and safety. Trial registration GSK study CTT200812; ClinicalTrials.gov NCT02729051 (submitted 31 March 2016).http://link.springer.com/article/10.1186/s12931-018-0724-0COPDExacerbationsFEV1Lung functionFluticasone furoate/umeclidinium/vilanterolRandomized controlled trial |
| spellingShingle | Peter R. Bremner Ruby Birk Noushin Brealey Afisi S. Ismaila Chang-Qing Zhu David A. Lipson Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study Respiratory Research COPD Exacerbations FEV1 Lung function Fluticasone furoate/umeclidinium/vilanterol Randomized controlled trial |
| title | Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study |
| title_full | Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study |
| title_fullStr | Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study |
| title_full_unstemmed | Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study |
| title_short | Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study |
| title_sort | single inhaler fluticasone furoate umeclidinium vilanterol versus fluticasone furoate vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease a randomized non inferiority study |
| topic | COPD Exacerbations FEV1 Lung function Fluticasone furoate/umeclidinium/vilanterol Randomized controlled trial |
| url | http://link.springer.com/article/10.1186/s12931-018-0724-0 |
| work_keys_str_mv | AT peterrbremner singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy AT rubybirk singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy AT noushinbrealey singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy AT afisisismaila singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy AT changqingzhu singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy AT davidalipson singleinhalerfluticasonefuroateumeclidiniumvilanterolversusfluticasonefuroatevilanterolplusumeclidiniumusingtwoinhalersforchronicobstructivepulmonarydiseasearandomizednoninferioritystudy |